Hacking the immune system could slow ageing — here’s how nature.com/articles/d4158…

MRI scans may help reduce unnecessary biopsies & diagnose more aggressive cancers.
✅ A meta-analysis of over 80,000 men found MRI led to:
⭕️Fewer biopsies overall (down to 28%)
⭕️Less detection of slow-growing cancers
⭕️Similar detection of high-risk cancers
👉This could mean…

The PI's contribution to the paper

Secondary analysis of TITAN trial shows that half of patients with mHSPC treated with apalutamide who experienced radiographic progression developed it without corresponding PSA progression. Great team Jikei Urology Takafumi Yanagisawa Keiichiro Mori Shahrokh F. Shariat

sciencedirect.com/science/articl…

Vitamin D appears to promote the immune response to cancer and the success of immunotherapy; now a mechanism is identified involving the gut microbiome interactions
science.org/doi/10.1126/sc…
science.org/doi/10.1126/sc…
Science Magazine Dr. Kathy McCoy Caetano Reis e Sousa The Crick

Outstanding #prostatecancer #tumorboard on #CEM24 ☝🏼☝🏼 ⁦Pawel Rajwa⁩ ⁦Marcin Miszczyk⁩ ⁦Piotr Chłosta⁩ ⁦Nyirády Dr. Péter⁩ ⁦Shahrokh F. Shariat⁩ ⁦Urologic Oncology Research MedUni Vienna⁩

Our latest paper on Intermediate Clinical Endpoints (ICE) for OS in prostate cancer trials:
- Abundant new evidence!
- For localised PCa, MFS is OK, but biochemical endpoints are NOT!
- No ICEs for CRPC, but PFS could be valid for HSPC? sciencedirect.com/science/articl…

Join Dr. Richard Lee at the start of #AUA24 as he presents on SLORs for Urology residency during May 2nd's SAU grants awardees presentation.

Click here to learn more ⏩ bit.ly/3U8zwxz

Genome sequencing of healthy people finds 2-5% unknowingly harbor important, actionable, disease- causing gene mutations. A new report Mount Sinai Health System adds to previous studies
cell.com/cell-reports-m… Iain S. Forrest, PhD Icahn School of Medicine at Mount Sinai Ron Do

Most viewed in the last 7 days from JAMA Oncology:

Do prostate cancer screening pathways that incorporate MRI and targeted biopsies outperform strategies that rely solely on PSA testing and systematic biopsy?

Presented at #EAU24

ja.ma/4awLFDp

#BladderCancer : En bloc resection technique shows promise. David D'Andrea, MD MedUni Wien joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the #eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. #WatchNow on UroToday > bit.ly/3V2hdfy

Two weeks to go! Central Europe Meeting 2024 #Vienna from 26th-27th April, hosted by
Shahrokh F. Shariat
MedUni Wien Urologic Oncology Research MedUni Vienna #CEM2024 #Urology #CCCVienna Bernhard Englinger Manuela Schmidinger Kilian Gust

Come & join this wonderful, interactive friendship meeting. Let’s discuss the hottest & controversial topics in practical & academic Urology. Everyone welcome! No registration free. When: April 26 & 27th in Vienna Austria. You will enjoy it! urologie.meduniwien.ac.at/ueber-uns/even…

MedUni Vienna among the best medical universities in the world meduniwien.ac.at/web/en/about-u…

Urologic Oncology Research MedUni Vienna Tamas Fazekas MD Shahrokh F. Shariat #CCCVienna

Vor Umbruch bei #Prostatakrebs -Screening - #Studie zeigt, dass #MR -Untersuchungen unnötige #Biopsien zum größten Teil verhindern könnten Tamas Fazekas MD MedUni Wien Urologic Oncology Research MedUni Vienna #Gesundheit #Medizin #Krebs #Onkologie go.apa.at/5DIydt4P

Read the new Paper from the #CCCVienna MedUni Wien Urologic Oncology Research MedUni Vienna Tamas Fazekas MD Shahrokh F. Shariat #ProstateCancer #MRI #Oncology #Overdiagnosis #PSA #Biopsies #JAMAOncology #Screening

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

More data showing expected rise across many cancers including #prostatecancer . Can we as a system handle this surge?